Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Fda crawled date : 2022 - 01 - 04 save search
Entera Bio Announces Successful EB613 End-of-Phase 2 Meeting with FDA
Published: 2022-01-04 (Crawled : 23:00) - biospace.com/
ENTX | $2.07 -6.76% -7.25% 160K
|
Health Technology
|
| O: 8.57%
H: 0.0%
C: -10.17%
AMGN | News | $273.085 -0.17% -0.17% 2.5M
|
Health Technology
|
| O: -0.41%
H: 0.0%
C: 0.0%
eb613 fda phase 2 613
Adverum Biotechnologies Granted Orphan Drug Designation by FDA for Gene Therapy Candidate in Preclinical Development for the Treatment of Blue Cone Monochromacy
Published: 2022-01-04 (Crawled : 23:00) - biospace.com/
ADVM | News | $10.19 -7.36% -7.95% 310K
|
Health Technology
|
| O: -1.54%
H: 1.04%
C: -5.73%
treatment fda gene therapy drug granted preclinical orphan drug therapy biotech iot pre-clinical designation
Oncternal Therapeutics Announces Agreement with U.S. FDA on Phase 3 Registrational Study Design for Zilovertamab in the Treatment of Mantle Cell Lymphoma
Published: 2022-01-04 (Crawled : 23:00) - biospace.com/
ONCT | $8.755 -0.11% -0.11% 1.6K
|
Health Technology
|
| O: 1.65%
H: 0.4%
C: -5.26%
treatment fda therapeutics cel phase 3 designation
Spero Therapeutics Announces Lifting of FDA Clinical Trial Hold on SPR720
Published: 2022-01-04 (Crawled : 19:00) - biospace.com/
SPRO | $1.41 -1.74% -1.77% 110K
|
Health Technology
|
| O: 3.96%
H: 0.0%
C: -5.33%
spr720 fda trial therapeutics
Melt Pharmaceuticals Submits INDs for MELT‑210 and MELT-400 to FDA
Published: 2022-01-04 (Crawled : 15:30) - biospace.com/
CTLT | $55.95 -0.14% 0.0% 2M
|
Health Technology
|
| O: -0.59%
H: 0.0%
C: 0.0%
HROW P | $10.275 -0.44% -0.44% 410K
|
Health Technology
|
| O: -0.23%
H: 0.12%
C: -5.67%
melt-400 fda als
FDA Grants Breakthrough Therapy Designation for Cullinan Oncology’s CLN-081 in Patients with Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer
Published: 2022-01-04 (Crawled : 15:00) - biospace.com/
CGEM | $18.9 13.38% 11.8% 1.2M
|
|
| O: 3.27%
H: 8.4%
C: -1.64%
cln-081 fda cel lung cancer therapy cancer breakthrough therapy designation
Entera Bio Announces Successful EB613 End-of-Phase 2 Meeting with FDA: FDA Agrees to Phase 3 Twelve Month Study with Lumbar Spine BMD (bone mineral density) as the Primary Endpoint
Published: 2022-01-04 (Crawled : 14:00) - globenewswire.com
ENTX | $2.07 -6.76% -7.25% 160K
|
Health Technology
|
| O: 8.57%
H: 0.0%
C: -10.17%
AMGN | News | $273.085 -0.17% -0.17% 2.5M
|
Health Technology
|
| O: -0.41%
H: 0.0%
C: 0.0%
eb613 fda phase 2 bone 613 spine phase 3
Everest Medicines Announces Taiwan FDA Has Accepted New Drug Application for Sacituzumab Govitecan in Second-Line Metastatic Triple-Negative Breast Cancer
Published: 2022-01-04 (Crawled : 01:00) - prnewswire.com
GILD | $67.07 0.06% 0.06% 8.3M
|
Health Technology
|
| O: 0.4%
H: 0.0%
C: 0.0%
new drug fda application drug cancer negative breast cancer
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.